Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Effect of increasing systemic arterial pressure

Pere Ginès, Llúcia Titó, Vicente Arroyo, Josep Llach, Joan Manuel Salmerón, Angels Ginès, Wladimiro Jiménez, Salvatore Badalamenti, Francisca Rivera, Joan Rodés

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The IV infusion of pharmacological doses (0.05 μg · kg-1 · min-1) of atrial natriuretic peptide to 16 patients with cirrhosis and ascites induced a significant increase in sodium excretion (65 ± 23 to 517 ± 231 μEq/min), urine volume (10.7 ± 2.3 to 15.7 ± 3.7 mL/min), and glomerular filtration rate (89 ± 4 to 110 ± 4 mL/min) in only 5 patients (responders). No significant changes in these parameters (15 ± 6 to 11 ± 4 μEq/min, 5.5 ± 1.0 to 4.2 ± 1.1 mL/min, and 81 ± 5 to 79 ± 6 mL/min, respectively) were observed in the remaining patients (nonresponders). Compared with responders, nonresponders had significantly lower baseline sodium excretion (P <0.02), urine flow (P <0.05), free water clearance (2.5 ± 0.9 vs. 6.9 ± 2.1 mL/min; P <0.05), and mean arterial pressure (82 ± 3 vs. 96 ± 2 mm Hg; P <0.01) and significantly higher plasma renin activity (16.3 ± 4.9 vs. 1.8 ± 0.2 ng · mL-1 · h-1; P <0.05) and aldosterone level (99 ± 24 vs. 13 ± 2 ng/dL; P <0.05). Atrial natriuretic peptide produced a similar reduction of arterial pressure in both groups. To investigate whether the blunted natriuretic response to atrial natriuretic peptide in nonresponders was caused by their lower arterial pressure, atrial natriuretic peptide was infused in 7 of these patients after increasing their arterial pressure to the levels of responders with norepinephrine. The increase in arterial pressure (from 81 ± 5 to 95 ± 5 mm Hg), which was not associated with significant changes in plasma renin activity and aldosterone concentration, did not reverse the blunted renal response to atrial natriuretic peptide in any of these patients. These results indicate that cirrhotic patients with blunted renal response to atrial natriuretic peptide are characterized by low arterial pressure, marked overactivity of the renin-aldosterone system, and severe sodium and water retention. Correction of hypotension without increasing effective blood volume does not restore renal insensitivity to atrial natriuretic peptide.

Original languageEnglish
Pages (from-to)280-286
Number of pages7
JournalGastroenterology
Volume102
Issue number1
Publication statusPublished - 1992

Fingerprint

Atrial Natriuretic Factor
Ascites
Arterial Pressure
Fibrosis
Kidney
Aldosterone
Renin
Sodium
Urine
Water
Blood Volume
Glomerular Filtration Rate
Hypotension
Norepinephrine
Pharmacology

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Ginès, P., Titó, L., Arroyo, V., Llach, J., Salmerón, J. M., Ginès, A., ... Rodés, J. (1992). Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Effect of increasing systemic arterial pressure. Gastroenterology, 102(1), 280-286.

Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Effect of increasing systemic arterial pressure. / Ginès, Pere; Titó, Llúcia; Arroyo, Vicente; Llach, Josep; Salmerón, Joan Manuel; Ginès, Angels; Jiménez, Wladimiro; Badalamenti, Salvatore; Rivera, Francisca; Rodés, Joan.

In: Gastroenterology, Vol. 102, No. 1, 1992, p. 280-286.

Research output: Contribution to journalArticle

Ginès, P, Titó, L, Arroyo, V, Llach, J, Salmerón, JM, Ginès, A, Jiménez, W, Badalamenti, S, Rivera, F & Rodés, J 1992, 'Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Effect of increasing systemic arterial pressure', Gastroenterology, vol. 102, no. 1, pp. 280-286.
Ginès, Pere ; Titó, Llúcia ; Arroyo, Vicente ; Llach, Josep ; Salmerón, Joan Manuel ; Ginès, Angels ; Jiménez, Wladimiro ; Badalamenti, Salvatore ; Rivera, Francisca ; Rodés, Joan. / Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Effect of increasing systemic arterial pressure. In: Gastroenterology. 1992 ; Vol. 102, No. 1. pp. 280-286.
@article{2a1bbd5c4dad4e3498694b5ceebd67e1,
title = "Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Effect of increasing systemic arterial pressure",
abstract = "The IV infusion of pharmacological doses (0.05 μg · kg-1 · min-1) of atrial natriuretic peptide to 16 patients with cirrhosis and ascites induced a significant increase in sodium excretion (65 ± 23 to 517 ± 231 μEq/min), urine volume (10.7 ± 2.3 to 15.7 ± 3.7 mL/min), and glomerular filtration rate (89 ± 4 to 110 ± 4 mL/min) in only 5 patients (responders). No significant changes in these parameters (15 ± 6 to 11 ± 4 μEq/min, 5.5 ± 1.0 to 4.2 ± 1.1 mL/min, and 81 ± 5 to 79 ± 6 mL/min, respectively) were observed in the remaining patients (nonresponders). Compared with responders, nonresponders had significantly lower baseline sodium excretion (P <0.02), urine flow (P <0.05), free water clearance (2.5 ± 0.9 vs. 6.9 ± 2.1 mL/min; P <0.05), and mean arterial pressure (82 ± 3 vs. 96 ± 2 mm Hg; P <0.01) and significantly higher plasma renin activity (16.3 ± 4.9 vs. 1.8 ± 0.2 ng · mL-1 · h-1; P <0.05) and aldosterone level (99 ± 24 vs. 13 ± 2 ng/dL; P <0.05). Atrial natriuretic peptide produced a similar reduction of arterial pressure in both groups. To investigate whether the blunted natriuretic response to atrial natriuretic peptide in nonresponders was caused by their lower arterial pressure, atrial natriuretic peptide was infused in 7 of these patients after increasing their arterial pressure to the levels of responders with norepinephrine. The increase in arterial pressure (from 81 ± 5 to 95 ± 5 mm Hg), which was not associated with significant changes in plasma renin activity and aldosterone concentration, did not reverse the blunted renal response to atrial natriuretic peptide in any of these patients. These results indicate that cirrhotic patients with blunted renal response to atrial natriuretic peptide are characterized by low arterial pressure, marked overactivity of the renin-aldosterone system, and severe sodium and water retention. Correction of hypotension without increasing effective blood volume does not restore renal insensitivity to atrial natriuretic peptide.",
author = "Pere Gin{\`e}s and Ll{\'u}cia Tit{\'o} and Vicente Arroyo and Josep Llach and Salmer{\'o}n, {Joan Manuel} and Angels Gin{\`e}s and Wladimiro Jim{\'e}nez and Salvatore Badalamenti and Francisca Rivera and Joan Rod{\'e}s",
year = "1992",
language = "English",
volume = "102",
pages = "280--286",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. Effect of increasing systemic arterial pressure

AU - Ginès, Pere

AU - Titó, Llúcia

AU - Arroyo, Vicente

AU - Llach, Josep

AU - Salmerón, Joan Manuel

AU - Ginès, Angels

AU - Jiménez, Wladimiro

AU - Badalamenti, Salvatore

AU - Rivera, Francisca

AU - Rodés, Joan

PY - 1992

Y1 - 1992

N2 - The IV infusion of pharmacological doses (0.05 μg · kg-1 · min-1) of atrial natriuretic peptide to 16 patients with cirrhosis and ascites induced a significant increase in sodium excretion (65 ± 23 to 517 ± 231 μEq/min), urine volume (10.7 ± 2.3 to 15.7 ± 3.7 mL/min), and glomerular filtration rate (89 ± 4 to 110 ± 4 mL/min) in only 5 patients (responders). No significant changes in these parameters (15 ± 6 to 11 ± 4 μEq/min, 5.5 ± 1.0 to 4.2 ± 1.1 mL/min, and 81 ± 5 to 79 ± 6 mL/min, respectively) were observed in the remaining patients (nonresponders). Compared with responders, nonresponders had significantly lower baseline sodium excretion (P <0.02), urine flow (P <0.05), free water clearance (2.5 ± 0.9 vs. 6.9 ± 2.1 mL/min; P <0.05), and mean arterial pressure (82 ± 3 vs. 96 ± 2 mm Hg; P <0.01) and significantly higher plasma renin activity (16.3 ± 4.9 vs. 1.8 ± 0.2 ng · mL-1 · h-1; P <0.05) and aldosterone level (99 ± 24 vs. 13 ± 2 ng/dL; P <0.05). Atrial natriuretic peptide produced a similar reduction of arterial pressure in both groups. To investigate whether the blunted natriuretic response to atrial natriuretic peptide in nonresponders was caused by their lower arterial pressure, atrial natriuretic peptide was infused in 7 of these patients after increasing their arterial pressure to the levels of responders with norepinephrine. The increase in arterial pressure (from 81 ± 5 to 95 ± 5 mm Hg), which was not associated with significant changes in plasma renin activity and aldosterone concentration, did not reverse the blunted renal response to atrial natriuretic peptide in any of these patients. These results indicate that cirrhotic patients with blunted renal response to atrial natriuretic peptide are characterized by low arterial pressure, marked overactivity of the renin-aldosterone system, and severe sodium and water retention. Correction of hypotension without increasing effective blood volume does not restore renal insensitivity to atrial natriuretic peptide.

AB - The IV infusion of pharmacological doses (0.05 μg · kg-1 · min-1) of atrial natriuretic peptide to 16 patients with cirrhosis and ascites induced a significant increase in sodium excretion (65 ± 23 to 517 ± 231 μEq/min), urine volume (10.7 ± 2.3 to 15.7 ± 3.7 mL/min), and glomerular filtration rate (89 ± 4 to 110 ± 4 mL/min) in only 5 patients (responders). No significant changes in these parameters (15 ± 6 to 11 ± 4 μEq/min, 5.5 ± 1.0 to 4.2 ± 1.1 mL/min, and 81 ± 5 to 79 ± 6 mL/min, respectively) were observed in the remaining patients (nonresponders). Compared with responders, nonresponders had significantly lower baseline sodium excretion (P <0.02), urine flow (P <0.05), free water clearance (2.5 ± 0.9 vs. 6.9 ± 2.1 mL/min; P <0.05), and mean arterial pressure (82 ± 3 vs. 96 ± 2 mm Hg; P <0.01) and significantly higher plasma renin activity (16.3 ± 4.9 vs. 1.8 ± 0.2 ng · mL-1 · h-1; P <0.05) and aldosterone level (99 ± 24 vs. 13 ± 2 ng/dL; P <0.05). Atrial natriuretic peptide produced a similar reduction of arterial pressure in both groups. To investigate whether the blunted natriuretic response to atrial natriuretic peptide in nonresponders was caused by their lower arterial pressure, atrial natriuretic peptide was infused in 7 of these patients after increasing their arterial pressure to the levels of responders with norepinephrine. The increase in arterial pressure (from 81 ± 5 to 95 ± 5 mm Hg), which was not associated with significant changes in plasma renin activity and aldosterone concentration, did not reverse the blunted renal response to atrial natriuretic peptide in any of these patients. These results indicate that cirrhotic patients with blunted renal response to atrial natriuretic peptide are characterized by low arterial pressure, marked overactivity of the renin-aldosterone system, and severe sodium and water retention. Correction of hypotension without increasing effective blood volume does not restore renal insensitivity to atrial natriuretic peptide.

UR - http://www.scopus.com/inward/record.url?scp=0026501805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026501805&partnerID=8YFLogxK

M3 - Article

VL - 102

SP - 280

EP - 286

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -